Margaret E. Maes

Margaret E. Maes

Auto-generated profile, based on publicly available information

Margaret E. Maes

Institute of Science and Technology Austria (ISTA)

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
MMMargaret E. Maes
Margaret E. Maes
CSCassandra L. Schlamp
Cassandra L. Schlamp
RNRobert W Nickells
Robert W Nickells

1 August 2019 in Neuroscience Letters
Verified
Journal Article
Open access
MMMargaret E. Maes
Margaret E. Maes
GCGloria Colombo
Gloria Colombo
RSRouven Schulz
Rouven Schulz
SSSandra Siegert
Sandra Siegert
Microglia have emerged as a critical component of neurodegenerative diseases. Genetic manipulation of microglia can elucidate their functional impact in disease. In neuroscience, recombinant viruses such as lentiviruses and adeno-associated viruses (AAVs) have been successfully used to target various cell types in the brain, although effective transduction of microglia is rare. In this review, we provide a short background of lentiviruses and AAVs, and strategies for designing recombinant viral vectors. Then, we will summarize recent literature on successful microglial transductions in vitro and in vivo, and discuss the current challenges. Finally, we provide guidelines for reporting the efficiency and specificity of viral targeting in microglia, which will enable the microglial research community to assess and improve methodologies for future studies.

25 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
NMNicole A. Muench
Nicole A. Muench
SPSonia Patel
Sonia Patel
MMMargaret E. Maes
Margaret E. Maes
RDRyan J. Donahue
Ryan J. Donahue
AIAkihiro Ikeda
Akihiro Ikeda
RNRobert W Nickells
Robert W Nickells
The important roles of mitochondrial function and dysfunction in the process of neurodegeneration are widely acknowledged. Retinal ganglion cells (RGCs) appear to be a highly vulnerable neuronal cell type in the central nervous system with respect to mitochondrial dysfunction but the actual reasons for this are still incompletely understood. These cells have a unique circumstance where unmyelinated axons must bend nearly 90° to exit the eye and then cross a translaminar pressure gradient before becoming myelinated in the optic nerve. This region, the optic nerve head, contains some of the highest density of mitochondria present in these cells. Glaucoma represents a perfect storm of events occurring at this location, with a combination of changes in the translaminar pressure gradient and reassignment of the metabolic support functions of supporting glia, which appears to apply increased metabolic stress to the RGC axons leading to a failure of axonal transport mechanisms. However, RGCs themselves are also extremely sensitive to genetic mutations, particularly in genes affecting mitochondrial dynamics and mitochondrial clearance. These mutations, which systemically affect the mitochondria in every cell, often lead to an optic neuropathy as the sole pathologic defect in affected patients. This review summarizes knowledge of mitochondrial structure and function, the known energy demands of neurons in general, and places these in the context of normal and pathological characteristics of mitochondria attributed to RGCs.

12 November 2019 in Scientific Reports
Verified
Journal Article
Open access
MMM. E. Maes
M. E. Maes
JGJ. A. Grosser
J. A. Grosser
RFR. L. Fehrman
R. L. Fehrman
CSC. L. Schlamp
C. L. Schlamp
RNRobert W Nickells
Robert W Nickells
BAX, a member of the BCL2 gene family, controls the committed step of the intrinsic apoptotic program. Mitochondrial fragmentation is a commonly observed feature of apoptosis, which occurs through the process of mitochondrial fission. BAX has consistently been associated with mitochondrial fission, yet how BAX participates in the process of mitochondrial fragmentation during apoptosis remains to be tested. Time-lapse imaging of BAX recruitment and mitochondrial fragmentation demonstrates that rapid mitochondrial fragmentation during apoptosis occurs after the complete recruitment of BAX to the mitochondrial outer membrane (MOM). The requirement of a fully functioning BAX protein for the fission process was demonstrated further in BAX/BAK-deficient HCT116 cells expressing a P168A mutant of BAX. The mutant performed fusion to restore the mitochondrial network. but was not demonstrably recruited to the MOM after apoptosis induction. Under these conditions, mitochondrial fragmentation was blocked. Additionally, we show that loss of the fission protein, dynamin-like protein 1 (DRP1), does not temporally affect the initiation time or rate of BAX recruitment, but does reduce the final level of BAX recruited to the MOM during the late phase of BAX recruitment. These correlative observations suggest a model where late-stage BAX oligomers play a functional part of the mitochondrial fragmentation machinery in apoptotic cells.

31 October 2019 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
RDRyan J. Donahue
Ryan J. Donahue
MMMargaret E. Maes
Margaret E. Maes
JGJoshua A. Grosser
Joshua A. Grosser
RNRobert W Nickells
Robert W Nickells

1 January 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MWMichael Wilhelm
Michael Wilhelm
NKNickolay V. Kukekov
Nickolay V. Kukekov
TSTravis L. Schmit
Travis L. Schmit
KBKatherine V. Biagas
Katherine V. Biagas
ASAndrew Sproul
Andrew Sproul
LGLloyd A. Greene
Lloyd A. Greene
We report that Sh3rf2, a homologue of the pro-apoptotic scaffold POSH (Plenty of SH3s), acts as an anti-apoptotic regulator for the c-Jun N-terminal kinase (JNK) pathway. siRNA-mediated knockdown of Sh3rf2 promotes apoptosis of neuronal PC12 cells, cultured cortical neurons, and C6 glioma cells. This death appears to result from activation of JNK signaling. Loss of Sh3rf2 triggers activation of JNK and its target c-Jun. Also, apoptosis promoted by Sh3rf2 knockdown is inhibited by dominant-negative c-Jun as well as by a JNK inhibitor. Investigation of the mechanism by which Sh3rf2 regulates cell survival implicates POSH, a scaffold required for activation of pro-apoptotic JNK/c-Jun signaling. In cells lacking POSH, Sh3rf2 knockdown is unable to activate JNK. We further find that Sh3rf2 binds POSH to reduce its levels by a mechanism that requires the RING domains of both proteins and that appears to involve proteasomal POSH degradation. Conversely, knockdown of Sh3rf2 promotes the stabilization of POSH protein and activation of JNK signaling. Finally, we show that endogenous Sh3rf2 protein rapidly decreases following several different apoptotic stimuli and that knockdown of Sh3rf2 activates the pro-apoptotic JNK pathway in neuronal cells. These findings support a model in which Sh3rf2 promotes proteasomal degradation of pro-apoptotic POSH in healthy cells and in which apoptotic stimuli lead to rapid loss of Sh3rf2 expression, and consequently to stabilization of POSH and JNK activation and cell death. On the basis of these observations, we propose the alternative name POSHER (POSH-eliminating RING protein) for the Sh3rf2 protein.